CJC-1295 DAC

The Growth Hormone Amplifier

Boost Growth Hormone Levels: Unlock the Benefits of CJC-1295 DAC

CJC-1295 DAC(Drug Affinity Complex) is a synthetic peptide that functions as a growth hormone releasing hormone (GHRH) analog. Its primary role is to enhance plasma growth hormone levels in the body. CJC-1295 DAC is a modification of a naturally occurring peptide with a longer half-life, achieved by adding a drug affinity complex to the molecule. This modification extends the duration of the peptide’s action, allowing it to remain active in the bloodstream for an extended period.

The peptide works by binding to the GHRH receptor, which in turn stimulates the release of growth hormone from the pituitary gland. The prolonged action of CJC-1295 DAC, due to its drug affinity complex, makes it particularly effective in promoting sustained growth hormone release, which can be beneficial for enhancing muscle growth, improving physical performance, and aiding in recovery and regeneration processes.

This peptide is of interest not only in bodybuilding and athletic communities for its potential benefits on muscle and performance but also in anti-aging research due to its capacity to increase growth hormone levels, which decline with age.

Potential Benefits Under Research

• Increased Growth Hormone Levels: By stimulating the release of growth hormone, CJC-1295 DAC can potentially enhance this hormone’s natural effects on the body.

• Enhanced Muscle Growth: Growth hormone is known for its role in muscle development. CJC-1295 DAC might help increase muscle mass and improve muscle strength.

• Improved Recovery Times: Increased levels of growth hormone can aid in recovery from injuries, particularly muscle damage, by enhancing tissue repair processes.

• Anti-Aging Effects: As growth hormone levels naturally decrease with age, CJC-1295 DAC could help restore higher levels, potentially improving skin elasticity, reducing wrinkles, and promoting a more youthful appearance.

• Fat Loss: Growth hormone plays a role in fat metabolism, so higher levels induced by CJC-1295 DAC could help reduce body fat.

• Increased Bone Density: Growth hormone has been linked to bone density improvements, suggesting that CJC-1295 DAC might be beneficial in preventing osteoporosis or strengthening bones.

Dosing Protocol for Research Purposes

• Twice a week at 100 mcg, OR 100 mcg daily (this dose works best for short-term treatment to elevate IGF1 above physiologic levels)

CJC-1295 Overview

Growth hormone releasing hormone (GHRH). has been modified a number of times to produce analogues that preserve some of the hormone’s effects while eliminating others. One of those modifications, CJC-1295, consists of just the first 29 amino acids of GHRH. This analogue of GHRH, which is technically a maleimido derivative of hGRF(l-29)., was created in an effort to produce a more soluble GH secretagogue that is easier to produce in large quantities but still preserves the physiologic actions of GHRH.

CJC-1295 Versus CJC-1295 DAC

CJC-1295 is a modified version of the first 29 amino acids of GHRH, which means it is chemically similar to other GHRH analogues, like Sermorelin. It is most similar to modified GRF (1-29), but the two peptides are not identical. A great deal of confusion arises because of the similarities between these peptides and because CJC-1295 was originally created with an added chemical compound called the drug affinity complex (DAC).

DAC is added to the molecule, with the help of a lysine linker, to protect the peptide while it circulates in the blood stream. By allowing peptides to bind to the common blood protein albumin, DAC helps to ensure that the half-life of CJC-1295 is much longer than similar molecules like GRF (1-29).

Originally, ConjuChem Biotechnologies, the
developer of DAC, referred to the molecule containing DAC as simply CJC-1295. Confusion arose, however, because the peptide was also being
offered without DAC. To avoid confusion, CJC-1295 that contains DAC is called CJC-1295-DAC and when it does not contain DAC it is referred to as CJC-1295 or CJC-1295-no DAC.

CJC-1295 Structure

Sequence: Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-Gln-Ser­Tyr-Arg-Lys-Val-Leu-Ala-G I n-Leu-Ser-Ala-Arg-Lys­Leu-Leu-G I n-Asp-1 le-Leu-Ser-Arg
Molecular Formula: C1s2H2s2N44042
Molecular Weight: 3367 .954 g/mol
PubChem CID: 56841945

CJC-1295-DAC Structure

Sequence: Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-Gln-Ser­Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys­Leu-Leu-Gln-Asp-lle-Leu-Ser-Arg-Lys-DAC Molecular Formula: C152H2s2N44042
Molecular Weight: 3647.954 g/mol
PubChem CID: 91976842

CJC-1295 DAC Research

CJC-1295 and Growth Hormone Release

As a derivative of GHRH, it should come as no surprise that CJC-1295 promotes the release of GH. Studies show that a single dose of CJC-1295 increases GH levels in mice by 2-10 times. Peak GH levels are reached approximately 2 hours after administration and the effects last for about six days. Unlike other GH secretagogues, CJC-1295 preserves the normal physiologic release of GH. That means that the normal circadian peaks and valleys seen in GH release remain intact and that CJC-1295 is a physiologic growth hormone-releasing factor.

Preserving physiologic release of GH even while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects. In particular, CJC-1295 has been demonstrated to preserve growth hormone’s physiologic effects of hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and myocardial(heart cell) function.

CJC-1295 and Growth

Studies in mice without normal GHRH physiology have shown that CJC-1295 preserves normal GH release. This makes the peptide potentially useful as a therapy for abnormal growth in a variety of mammalian species, humans included. Preserving normal pulsatile release of GH is critical to ensuring proper release of downstream hormones, such as insulin-like growth factor-2 (IGF-1).

CJC-1295 and Infertility

Research from the early 1990s suggests that CJC-1295 and other GRF analogues may be useful in promoting ovulation in infertile female patients. Scientists have long known that ovulation is dependent on IGF-1 and that it is also likely influenced by GH release and cycling. Research in animal models of superovulation has helped to confirm these theories by showing that both GH and IGF-1 levels rise significantly surrounding the time of ovulation. Further, these studies indicate that exogenous administration of GH secretagogues, like CJC-1295, is enough to cause appropriate ovulation. There is some speculation that CJC-1295 and other analogues may even be useful in male infertility by helping to regulate sperm production. This latter hypothesis has yet to be tested.

CJC-1295 is a growth hormone secretagogue designed to have a long plasma half-life and to preserve the physiologic patterns inherent in the GH axis. On both accounts, the molecule has been a success.CJC-1295 has experienced limited interest in research settings due to the advent of a number of similar molecules and because of the proprietary nature of the molecule’s structure. Now that CJC-1295 can be manufactured at will, there is likely to be renewed interest in its properties, particularly as they apply to the increasingly frustrating problem of human infertility.

CJC-1295 exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. 

Article Author

• CJC-1295 WITHOUT DAC: A saturation dose of 100 mcg is typically used (1 mg/kg), as any higher dosage adds minimally to the pulse of GH released.
  CJC-1295 WITH DAC: Twice a week at 100 mcg, OR 100 mcg daily (this dose works best for short-term treatment to elevate IGF1 above physiologic levels).

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Guide to Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [4] under the referenced citations.

 Referenced Citations

1. M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. 
2. M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. 
3. A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no.9, pp. 1228–1232, Oct. 1991. 
4. Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin &Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique.(2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary In Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.